Mazurov, A V <br/><br/>
Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.  [electronic resource] 

 -  Platelets  Dec 2002 
 - 465-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0953-7104 
<br/><br/><label>Standard No.: </label>10.1080/0953710021000057839  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary--adverse effects<br/>Animals<br/>Antibodies--blood<br/>Antibodies, Monoclonal--adverse effects<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--adverse effects<br/>Male<br/>Mice<br/>Middle Aged<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--pharmacokinetics<br/>Platelet Count<br/>Platelet Glycoprotein GPIIb-IIIa Complex--immunology<br/>Reoperation<br/>Risk Assessment<br/>Safety